| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/23/2014 | WO2014014427A1 Modified release pharmaceutical tablet formulations |
| 01/23/2014 | WO2014014364A1 Injectable antibiotic formulations and their methods of use |
| 01/23/2014 | WO2014014363A1 Injectable antibiotic formulations and their methods of use |
| 01/23/2014 | WO2014014348A1 Gastro-retentive drug delivery system |
| 01/23/2014 | WO2014014314A1 Hetrocyclic derivative having dual inhibitory activity |
| 01/23/2014 | WO2014014270A1 Isoquinoline-5-carboxamide derivative having inhibitory activity for protein kinase |
| 01/23/2014 | WO2014014154A1 Antioxidant stabilising composition comprising alloferon |
| 01/23/2014 | WO2014014150A1 Pharmaceutical composition comprising antiviral neuraminidase inhibitor and permeation enhancer for enhanced oral bioavailability |
| 01/23/2014 | WO2014014050A1 1-(cycloalkyl-carbonyl)proline derivative |
| 01/23/2014 | WO2014013928A1 Stabilized solid preparation for internal use |
| 01/23/2014 | WO2014013903A1 Liquid composition containing taxane-based active ingredient, process for producing same, and liquid medicinal preparation |
| 01/23/2014 | WO2014013793A1 METHOD FOR PRODUCING β-GLUCAN |
| 01/23/2014 | WO2014013727A1 Immunemodulating agent |
| 01/23/2014 | WO2014013664A1 Prophylactic/therapeutic agent for influenza virus infection |
| 01/23/2014 | WO2014013535A1 Mucosal healing promoter |
| 01/23/2014 | WO2014013511A2 Rufinamide solid dispersion |
| 01/23/2014 | WO2014013505A2 Amorphous vildagliptin |
| 01/23/2014 | WO2014013498A1 Amorphous coprecipitates of linezolid |
| 01/23/2014 | WO2014013497A1 Fatty acid derivatives for use in a method of treating depression and associated conditions |
| 01/23/2014 | WO2014013469A1 Carbamate/urea derivatives |
| 01/23/2014 | WO2014013465A2 Salts and hydrates of antipsychotics |
| 01/23/2014 | WO2014013338A2 Compounds for the treatment of alzheimer's disease |
| 01/23/2014 | WO2014013313A1 Process for improved opioid synthesis |
| 01/23/2014 | WO2014013311A1 Process for improved opioid synthesis |
| 01/23/2014 | WO2014013309A1 Indolecarbonitriles as selective androgen receptor modulators |
| 01/23/2014 | WO2014013258A1 Stem cell microparticles |
| 01/23/2014 | WO2014013254A1 Inhibitors of nkx2.5 for vascular remodelling |
| 01/23/2014 | WO2014013231A1 Materials and methods for treating pten mutated or deficient cancer |
| 01/23/2014 | WO2014013184A1 Use of epigenome-modifying compounds for the treatment of genetic muscular diseases linked to a protein-conformational disorder |
| 01/23/2014 | WO2014013182A1 Imidazopyridine derivative used in the treatment of diabetes |
| 01/23/2014 | WO2014013181A1 Thiophene derivatives used in the treatment of diabetes |
| 01/23/2014 | WO2014013119A1 Composition and culture media comprising hyaluronan and an essential polyunsaturated fatty acid selected from between linoleic acid and docosahexaenoic acid |
| 01/23/2014 | WO2014013117A1 Chromenopyrazole diones as cannabinoid quinone derivatives having anti-tumour activity |
| 01/23/2014 | WO2014013115A1 Beta-lactam apaf-1-inhibitor compounds |
| 01/23/2014 | WO2014013076A1 Hexahydropyrrolothiazine compounds |
| 01/23/2014 | WO2014013025A1 Baclofen and acamprosate based therapy of macular degeneration disorders |
| 01/23/2014 | WO2014013014A1 Jak inhibitors for activation of epidermal stem cell populations |
| 01/23/2014 | WO2014013008A1 Gastro-resistant delayed release pharmaceutical form |
| 01/23/2014 | WO2014013002A1 Aqueous transparent oil-in-water emulsion comprising an emulsified carotenoid |
| 01/23/2014 | WO2014012964A1 New antifibrinolytic compounds |
| 01/23/2014 | WO2014012954A1 Treatment of partly controlled or uncontrolled severe asthma |
| 01/23/2014 | WO2014012942A1 Use of vegfr-3 inhibitors for treating hepatocellular carcinoma |
| 01/23/2014 | WO2014012935A1 Substituted aminoindane- and aminotetralincarboxylic acids and use thereof |
| 01/23/2014 | WO2014012934A1 Novel 5-aminotetrahydroquinoline-2-carboxylic acids and use thereof |
| 01/23/2014 | WO2014012902A2 Melanosome transport inhibition for the treatment of melanoma |
| 01/23/2014 | WO2014012889A1 Anti-angiogenic compounds |
| 01/23/2014 | WO2014012871A1 Oleacein for treating or preventing diseases resulting from atherosclerotic plaques |
| 01/23/2014 | WO2014012859A1 Fumaric acid salt of 9-[4-(3-chloro-2-fluoro-phenylamino)-7-methoxy- chinazolin-6-yloxy]-1,4-diaza-spiro[5.5]undecan-5-one, its use as medicament and the preparation thereof |
| 01/23/2014 | WO2014012858A1 Pyridinone derivatives as tissue transglutaminase inhibitors |
| 01/23/2014 | WO2014012851A1 Arylethynyl derivatives |
| 01/23/2014 | WO2014012849A1 A new crystal form of cefoperazone sodium |
| 01/23/2014 | WO2014012805A1 Pharmaceutical compositions containing oligomeric lactic acid |
| 01/23/2014 | WO2014012653A1 Pharmaceutical patch for transdermal administration of tapentadol |
| 01/23/2014 | WO2014012614A1 Fused triazole derivatives as gamma secretase modulators |
| 01/23/2014 | WO2014012593A1 Alkyl substituted 3-hydroxypyridines for the treatment of depression |
| 01/23/2014 | WO2014012571A1 Complex of agomelatine and cyclodextrin |
| 01/23/2014 | WO2014012511A1 N-(3-heteroarylaryl)-4-arylarylcarboxamtdes and analogs as hedgehog pathway inhibitors and use thereof |
| 01/23/2014 | WO2014012495A1 Chiral α-methylene-β-lactam compound and preparation method and application thereof |
| 01/23/2014 | WO2014012480A1 Polymorphs of deuterated omega-diphenylurea or salts thereof |
| 01/23/2014 | WO2014012467A1 Diarylaniline or diarylpyridinamine compound and preparation method and medical use thereof |
| 01/23/2014 | WO2014012466A1 Compounds of diarylanilines and diarylpyridinamines, preparation method therefor, and uses thereof |
| 01/23/2014 | WO2014012428A1 Oxazolidinone derivative, preparation method thereof and use thereof in medicine |
| 01/23/2014 | WO2014012401A1 Benzo-seven-member heterocyclic derivative and preparation method of benzo-seven-member heterocyclic derivative and medical application of benzo-seven-member heterocyclic derivative |
| 01/23/2014 | WO2014012360A1 Nitrogenous heterocyclic derivatives and their application in drugs |
| 01/23/2014 | WO2014012236A1 Dabigatran etexilate derivative and preparation method and application thereof |
| 01/23/2014 | WO2013188763A9 Compositions for treating cancer and methods for making the same |
| 01/23/2014 | WO2013181331A3 Polyphenol-reactive oxygen species compositions and methods |
| 01/23/2014 | WO2013175494A3 Controlled release pharmaceutical formulations of direct thrombin inhibitors |
| 01/23/2014 | WO2013174930A3 7-oxo-thiazolopyridine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease |
| 01/23/2014 | WO2013174576A3 Vegetable-based skin care composition comprising a replacement for petrolatum |
| 01/23/2014 | WO2013171764A3 Ophthalmic formulations |
| 01/23/2014 | WO2013167112A8 Composition for nasal application |
| 01/23/2014 | WO2013166282A3 Methods and compositions for treating bacterial infection |
| 01/23/2014 | WO2013153451A3 Controlled release formulations of opioids |
| 01/23/2014 | WO2013151597A3 (1,2,3-triazolyl) sulfonyl derivatives |
| 01/23/2014 | WO2013082345A8 Aryl dihydropyridinones and piperidinones as mgat2 inhibitors |
| 01/23/2014 | WO2012072256A3 Once daily formulation of lacosamide |
| 01/23/2014 | US20140024719 Antiseptic compositions, methods and systems |
| 01/23/2014 | US20140024717 Process For The Preparation Of A Sulfated Derivative Of 3,5-Diiodo-O-[3-Iodophenyl]-L-Tyrosine |
| 01/23/2014 | US20140024716 Composition Comprising S-Allyl-L-Cysteine as Active Ingredient for Preventing or Treating Gastrointestinal Disorders |
| 01/23/2014 | US20140024715 Method and kit for admiinistering gamma-glutamyl-d-cysteine for the prevention of reperfusion injury following ischemic stroke |
| 01/23/2014 | US20140024713 Use of nitrated lipids for treatment of side effects of toxic medical therapies |
| 01/23/2014 | US20140024712 Acetyl l-carnitine for the preparation of a medicament for the prevention of painful peripheral neuropathy in patients with type 2 diabetes |
| 01/23/2014 | US20140024710 5-aminolevulinic acid derivatives, methods for their preparation and uses thereof |
| 01/23/2014 | US20140024707 Small molecule antagonists of bacterial quorum-sensing receptors |
| 01/23/2014 | US20140024706 Composition comprising scirpusin a and scirpusin b and anti-adipogenesis/anti-obesity potential thereof |
| 01/23/2014 | US20140024703 Novel Block Copolymer, Micelle Preparation, And Anticancer Agent Containing The Same As Active Ingredient |
| 01/23/2014 | US20140024702 Cancer gene therapy using nucleic acids encoding us28 and g-protein |
| 01/23/2014 | US20140024700 Blood-borne mirnas as surrogate markers of drug efficacy for cardiac conditions |
| 01/23/2014 | US20140024698 Methods for treating progeroid laminopathies using oligonucleotide analogues targeting human lmna |
| 01/23/2014 | US20140024697 Co-crystals of duloxetine and cox-inhibitors for the treatment of pain |
| 01/23/2014 | US20140024695 Methods of treating arthritic conditions using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline 1,3-dione |
| 01/23/2014 | US20140024693 Topical composition |
| 01/23/2014 | US20140024687 Combinations of Vascular Disrupting Agents with Inhibitor of Apoptosis Proteins Antagonists |
| 01/23/2014 | US20140024686 Use of glu-tubulin as a biomarker of drug response to furazanobenzimidazoles |
| 01/23/2014 | US20140024683 Chloride channel and chloride transporter modulators for therapy in smooth muscle diseases |
| 01/23/2014 | US20140024682 Pharmaceutical compounds |
| 01/23/2014 | US20140024678 Stable laquinimod preparations |
| 01/23/2014 | US20140024677 Methods for inducing mitochondrial biogenesis |
| 01/23/2014 | US20140024675 Crystalline forms of a prolyl hydroxylase inhibitor |